Previous Article | Next Article ![]()
Journal of Clinical Microbiology, February 2001, p. 811-815, Vol. 39, No. 2
Sera & Vaccines Central Research Laboratory,
00-725 Warsaw,1 and Medical Center for
Postgraduate Education, 00-416 Warsaw,2
Poland
Received 23 August 2000/Returned for modification 22 October
2000/Accepted 11 November 2000
About 2.5 years after the first isolation of the VanA phenotype of
vancomycin-resistant Enterococcus faecium (VREM) in Poland, the first VREM strains with the VanB phenotype have emerged
independently in two different Warsaw hospitals. In one of these the
VREM strain was selected during the long-term antimicrobial treatment
of a patient with a wide variety of infection risk factors who died after 3 months of hospitalization. The strain was found to contain the
transferable vanB2 gene cluster variant of the polymorphic type that was identified earlier in vancomycin-resistant enterococci from several different countries. In the course of infection the strain
underwent genetic diversification due to DNA recombination.
In the middle of June 1999, a
68-year-old woman with acute pancreatitis was subjected to surgical
evacuation of necrotic tissues and extraperitoneal drainage in a Warsaw
hospital. Having developed septic shock, she was transferred from the
surgical ward to the intensive care unit (ICU). Various risk factors
for infection were identified in the patient, and these included
obesity, diabetes, adult respiratory distress syndrome, intubation,
tracheostomy, ventilation, gastric tube, intravenous central catheter,
total parenteral nutrition, continuous extraperitoneal lavage, urinary catheter, prolonged hospitalization, and intensive antibiotic therapy.
The following antimicrobials were used for the treatment in the ICU:
metronidazole, cefoperazone, imipenem, vancomycin, amikacin,
piperacillin with tazobactam, tobramycin, ciprofloxacin, ceftazidime, co-trimoxazole, and fluconazole. Several different pathogens were recovered from the patient during this period including a Klebsiella pneumoniae strain that produced an
extended-spectrum Altogether four VREM isolates were collected during the treatment
(Table 1); three were identified in
clinical samples from the patient (skin lesion, peritoneum, and stool),
and one was identified from the patient's environment (the patient's
bedsheet). No vancomycin-resistant enterococci (VRE) were recovered
during the testing of other patients, medical personnel, and the entire ICU environment that was performed immediately after isolation of the
first VREM isolate. In order to prevent strain dissemination, the
patient was isolated with dedicated medical personnel, and advanced
infection control procedures were introduced into the ward according to
the guidelines of the Centers for Disease Control and Prevention
(11). The preventive action was successful, as no VRE have
been isolated in the hospital since that time.
0095-1137/01/$04.00+0 DOI: 10.1128/JCM.39.2.811-815.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Vancomycin-Resistant Enterococcus
faecium Strain Carrying the vanB2 Gene Variant in a
Polish Hospital
ska,2
os,2 and
![]()
ABSTRACT
Top
Abstract
Case Report
References
![]()
CASE REPORT
Top
Abstract
Case Report
References
-lactamase, a Pseudomonas aeruginosa
strain resistant to imipenem, a methicillin-resistant
Staphylococcus aureus (MRSA) strain, a vancomycin-susceptible Enterococcus faecium strain, and a
vancomycin-resistant E. faecium (VREM) isolate. Vancomycin
was introduced into therapy on the 12th day of hospitalization, after
the first isolation of MRSA, and was used in three therapeutic courses
of at least 15 days each. The first VREM isolate was cultured from a
skin lesion at the end of August 1999, after 52 days (in total) of vancomycin therapy. The patient died after 90 days of hospitalization with symptoms of generalized infection and multiorgan failure.
TABLE 1.
Selected clinical data for the clinical isolates and PFGE
typing, mating, and vanB gene sequence and
polymorphism results
Microbiology. The VREM isolates were subjected to detailed microbiological and epidemiological analyses. Genus identification was performed as described by Facklam and Collins (9), and the species was identified by the API Rapid ID32 STREP test (bioMérieux, Charbonnieres-les-Bains, France), supplemented by potassium tellurite reduction, motility, and pigment production tests (9). The MICs of different antimicrobial agents were evaluated by the agar dilution method according to NCCLS guidelines (17) and by the Etest in the case of quinupristin-dalfopristin and linezolid (the linezolid susceptibility data were interpreted according to the manufacturer's recommendations). Antimicrobial standards were supplied by the corresponding manufacturers. Enterococcus faecalis ATCC 29212, S. aureus ATCC 29213, and E. faecalis V583, the standard VanB phenotype strain (8, 22), were used as reference strains. The isolates were characterized by the high level of resistance to vancomycin (MICs, 128 to 256 µg/ml) and susceptibility to teicoplanin (MICs, 0.25 to 1 µg/ml), which suggested the VanB phenotype of vancomycin resistance. Additionally, they were resistant to penicillin (MICs, 128 µg/ml), ampicillin (MICs, 64 µg/ml), ciprofloxacin (MICs, 16 to 64 µg/ml), and chloramphenicol (MICs, 32 µg/ml) and also to high concentrations of aminoglycosides (gentamicin MICs, >1,024 µg/ml; streptomycin MICs, >2,048 µg/ml). The only antimicrobials to which the isolates were susceptible were tetracycline (MICs, 0.25 to 0.5 µg/ml), quinupristin-dalfopristin (MICs, 0.5 µg/ml), and linezolid (MICs, 1 µg/ml). The susceptibility testing revealed the multidrug resistance phenotype of the VREM isolates.
The vancomycin resistance transfer experiment was carried out with the isolates by the filter-mating procedure described by Klare et al. (15). E. faecium 64/3, which is resistant to rifampin and fusidic acid (28), was used as a recipient. The results are listed in Table 1. All but one isolate (isolate 8672) produced transconjugants at an efficiency of about 10
5
per donor cell, which indicated that the vancomycin resistance determinants were transferable and had a relatively high transmission potential. Evaluation of the MICs for the recombinant strains revealed
that resistance to no other drug was cotransferred with the resistance
to vancomycin (data not shown).
Clinical isolates were typed by pulsed-field gel electrophoresis (PFGE)
with a CHEF DRII system (Bio-Rad, Hercules, Calif.). DNA purification
and digestion with the SmaI restriction enzyme (MBI
Fermentas, Vilnius, Lithuania) were performed as described by Clark et
al. (5), and the electrophoresis was run under the
conditions described by de Lencastre et al. (7). PFGE
results were interpreted by the criteria proposed by Tenover et al.
(26). The results are shown in Fig.
1 and Table 1. All isolates were found to
represent a single PFGE type; however, one of these, isolate 8672, produced PFGE pattern a2, which differed by five DNA bands from the
pattern for the predominant one, PFGE pattern a1. These data suggested
that the patient was originally infected with a single VREM strain
which underwent some genetic differentiation with time.
|
sk, Poland). The vanB gene was detected by specific PCR with two different pairs of primers, the
vanB and vanB consensus primers, and the cycling
conditions used were those described originally (5, 6).
For all the isolates the PCR with the vanB primers, which
are specific for the vanB1 gene variant (5, 6),
amplified products of about 1.1 kb instead of 433 bp, as predicted for
vanB1 and obtained for the vanB1-containing V583
E. faecalis control strain (8, 21, 22). The
vanB consensus primers, which amplify specific products from
all vanB gene variants known to date (6),
produced amplicons of about 500 bp, which corresponded well with the
expected size of 484 bp. These data confirmed that the isolates were of the VanB phenotype and revealed that this phenotype was determined by a
gene cluster variant which was different from vanB1.
The vanB gene-containing 1.1-kb PCR product obtained for
isolate 8672 was subjected to direct DNA sequencing. Sequencing
reactions (24) were performed with the use of primers
vanB (5) supplemented by internal primers
5'-GACAAATCACTGGCC-3' and 5'-ATGGCTTCTTGCATAGC-3' and an ABI 310 PRISM automatic system (PE Biosystems, Foster
City, Calif.). It was found that the PCR product encompassed the 896-bp fragment of the vanB coding region starting from its 5' end
(out of 1,029 bp altogether) and the 201-bp fragment of the
vanHB reading frame that is located directly
upstream of vanB (with an overlap of 8 bp). This indicated
that, similarly to known vanB2 and vanB3 variants
(10, 18), the 5' primer of the vanB primer pair
(5) did not anneal to the vanB coding region;
however, it must have been complementary to a sequence present within
the vanHB gene, which seems to be unique
(6). The vanB gene sequence was found to be
identical to the corresponding part of one of vanB2 variants identified previously in Rochester, Minn. (GenBank accession no. U94526) (18) and differed by a single base pair from
a vanB2 gene sequenced in Taiwan (GenBank accession no.
Z83305).
Restriction fragment length polymorphism (RFLP) analysis of the
vanB2 gene cluster was studied as proposed by Dahl et
al. (6). DNA fragments encompassing the
vanRB, vanSB,
vanYB, vanW, vanHB, vanB, and
vanXB genes were amplified by long PCR (L-PCR) with the use of primer vanB long, and the resulting L-PCR
products were analyzed with the use of the DraI and
PagI (an isoschizomer of BspHI) restriction
enzymes (MBI Fermentas). The results are shown in Fig.
2A and Table 1. L-PCR products of the
expected size of about 6 kb were obtained for all isolates analyzed.
The amplified regions were found to represent a single polymorph, which
was originally identified as RFLP-2 in vanB2 and
vanB3 gene clusters from E. faecium and E. faecalis isolates collected in Norway, Sweden, the United Kingdom,
Germany, and the United States (6).
|
sk (12) with the identification of
VREM of the VanA phenotype (1). This isolation was
followed by a large and complicated outbreak in two different
hematological wards of the center (14, 23).
Data presented in this work document one of the first two incidences of
a VREM strain expressing the VanB phenotype (8, 21, 22) in
Poland. The strain was isolated from a single patient located in the
ICU of a Warsaw hospital who was particularly prone to nosocomial
infection. Due to immediate introduction of strict infection control
procedures (11), the VREM strain was most likely
eradicated from the hospital environment. The detailed molecular
analysis revealed that its phenotype was determined by the
vanB2 gene cluster variant, which resided within a
transferable DNA molecule. During the infection process the strain
underwent genetic diversification due to a DNA rearrangement that also
affected the vanB locus. The VanB phenotype was originally
reported by Sahm et al. (22) in 1989 and was described by
Quintiliani et al. (21) in 1993, and since then it has
spread in several countries (6). It is determined by a
cluster of genes located within composite transposons that may be
horizontally transmitted between strains either by themselves or by a
plasmid-mediated or other conjugative element-mediated process
(3, 4, 19, 20, 29). Several works carried out with VanB
strains of VRE from different countries (6, 8, 10, 18)
revealed a certain degree of heterogeneity of the vanB gene
sequence (vanB1, vanB2, and vanB3
variants) and of RFLP analysis of the vanB gene cluster (RFLP-1, -2, and -2*). Identification of the next case of infection with the vanB2 variant present in the context of the RFLP-2
polymorph of the gene cluster confirms the earlier observation of the
high degree of stability of the vanB-region sequences and
the hypothesis that they have a common evolutionary origin
(6).
| |
ACKNOWLEDGMENTS |
|---|
We thank Stephen Murchan for critical reading of the manuscript; Patrice Courvalin, who kindly provided E. faecalis V583; and Wolfgang Witte for strain E. faecium 64/3.
This work was partially financed by a grant from the Polish Committee for Scientific Research (grant KBN 4P05A 016 19) and by the U.S.-Poland Maria Sklodowska-Curie Joint Found II (grant MZ/NIH-98-324).
| |
FOOTNOTES |
|---|
*
Corresponding author. Mailing address: Sera & Vaccines
Central Research Laboratory, ul. Che
mska 30/34, 00-725 Warsaw,
Poland. Phone: (48) 22-841 33 67. Fax: (48) 22-841 29 49. E-mail:
waleria{at}urania.il.waw.pl.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Arthur, M.,
C. Molinas,
F. Depardieu, and P. Courvalin.
1993.
Characterization of Tn1546, a Tn3-related transposon conferring glycopeptide resistance by synthesis of depsipeptide peptidoglycan precursors in Enterococcus faecium BM4147.
J. Bacteriol.
175:117-127 |
| 2. |
Bell, J. M.,
J. C. Paton, and J. Turnidge.
1998.
Emergence of vancomycin-resistant enterococci in Australia: phenotypic and genotypic characteristics of isolates.
J. Clin. Microbiol.
36:2187-2190 |
| 3. |
Boyce, J. M.,
S. M. Opal,
J. W. Chow,
M. J. Zervos,
G. Potter-Bynoe,
C. B. Sherman,
R. L. C. Romulo,
S. Fortna, and A. A. Medeiros.
1994.
Outbreak of multidrug-resistant Enterococcus faecium with transferable vanB class vancomycin resistance.
J. Clin. Microbiol.
32:1148-1153 |
| 4. |
Carias, L. L.,
S. D. Rudin,
C. J. Donskey, and L. B. Rice.
1998.
Genetic linkage and cotransfer of a novel, vanB-containing transposon (Tn5382) and a low-affinity penicillin-binding protein 5 gene in a clinical vancomycin-resistant Enterococcus faecium isolate.
J. Bacteriol.
180:4426-4434 |
| 5. |
Clark, N.,
R. Cooksey,
B. Hill,
J. Swenson, and F. Tenover.
1993.
Characterization of glycopeptide-resistant enterococci from U.S. hospitals.
Antimicrob. Agents Chemother.
37:2311-2317 |
| 6. |
Dahl, K. H.,
G. Skov Simonsen,
Ø. Olsvik, and A. Sundsfjord.
1999.
Heterogeneity in vanB gene cluster of genetically diverse clinical strains of vancomycin-resistant enterococci.
Antimicrob. Agents Chemother.
43:1105-1110 |
| 7. | de Lencastre, H., E. P. Severina, R. B. Roberts, B. N. Kreiswirth, and A. Tomasz. 1996. Testing the efficacy of a molecular surveillance network: methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus faecium (VREF) genotypes in six hospitals in the metropolitan New York City area. The BARG Initiative Pilot Study Group. Bacterial Antibiotic Resistance Group. Microb. Drug Resist. 2:343-351[Medline]. |
| 8. | Evers, S., P. E. Reynolds, and P. Courvalin. 1994. Sequence of the vanB and ddl genes encoding D-alanine:D-lactate and D-alanine:D-alanine ligases in vancomycin-resistant Enterococcus faecalis V583. Gene 140:97-102[CrossRef][Medline]. |
| 9. |
Facklam, R., and M. D. Collins.
1989.
Identification of Enterococcus species isolated from human infections by a conventional test scheme.
J. Clin. Microbiol.
27:731-734 |
| 10. |
Gold, H. S.,
S. Ünal,
E. Cercenado,
C. Thauvin-Eliopulos,
G. M. Eliopulos,
C. B. Wennerstein, and R. C. Moellering, Jr.
1993.
A gene conferring resistance to vancomycin but not teicoplanin in isolates of Enterococcus faecalis and Enterococcus faecium demonstrates homology with vanB, vanA, and vanC genes of enterococci.
Antimicrob. Agents Chemother.
37:1604-1609 |
| 11. | The Hospital Infection Control Practices Advisory Committee. 1995. Recommendations for preventing the spread of vancomycin resistance: recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). Am. J. Infect. Control 23:87-94[CrossRef][Medline]. |
| 12. |
Hryniewicz, W.,
K. Szczypa,
M. Bronk,
A. Samet,
A. Hellmann, and K. Trzci ski.
1999.
First report of vancomycin-resistant Enterococcus faecium isolated in Poland.
Clin. Microbiol. Infect.
5:503-505[Medline].
|
| 13. |
Hryniewicz, W.,
T. Zar ba, and M. Kawalec.
1998.
Susceptibility patterns of Enterococcus spp. isolated in Poland during 1996.
Int. J. Antimicrob. Agents
10:303-307[CrossRef][Medline].
|
| 14. |
Kawalec, M.,
M. Gniadkowski, and W. Hryniewicz.
2000.
Outbreak of vancomycin-resistant enterococci in a hospital in Gda sk, Poland, due to horizontal transfer of different Tn1546-like transposon variants and clonal spread of several strains.
J. Clin. Microbiol.
38:3317-3322 |
| 15. | Klare, I., E. Collatz, S. Al.-Obeid, J. Wagner, A. C. Rodloff, and W. Witte. 1992. Glykopeptidresistenz bei Enterococcus faecium aus Besiedlungen und Infectionen von Patienten aus Intensivstationen Berliner Kliniken und einem Transplantationszentrum. ZAC Z. Antimikrob. Antineoplast. Chemother. 10:45-53. |
| 16. | Leclercq, R., E. Derlot, J. Duval, and P. Courvalin. 1988. Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. N. Engl. J. Med. 319:157-161[Medline]. |
| 17. | National Committee for Clinical Laboratory Standards. 2000. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard In Performance standards for antimicrobial susceptibility testing; M7-A5, 5th ed., vol. 20, no. 2. National Committee for Clinical Laboratory Standards, Wayne, Pa. |
| 18. |
Patel, R.,
J. R. Uhl,
P. Kohner,
M. K. Hopkins,
J. M. Steckelberg,
B. Kline, and F. R. Cockerill, III.
1998.
DNA sequence variation within vanA, vanB, vanC-1, and vanC-2/3 genes of clinical Enterococcus isolates.
Antimicrob. Agents Chemother.
42:202-205 |
| 19. | Quintiliani, R., Jr., and P. Courvalin. 1994. Conjugal transfer of the vancomycin-resistance determinant vanB between enterococci involves the movement of large genetic elements from chromosome to chromosome. FEMS Microbiol. Lett. 119:359-364[CrossRef][Medline]. |
| 20. | Quintiliani, R., Jr., and P. Courvalin. 1996. Characterization of Tn1547, composite transposon flanked by the IS16 and IS256-like elements, that confers vancomycin resistance in Enterococcus faecalis BM4281. Gene 172:1-8[CrossRef][Medline]. |
| 21. | Quintiliani, R., Jr., S. Evers, and P. Courvalin. 1993. The vanB gene confers various levels of self-transferable resistance to vancomycin in enterococci. J. Infect. Dis. 167:1220-1223[Medline]. |
| 22. |
Sahm, D. F.,
J. Kissinger,
M. S. Gilmore,
P. R. Murray,
R. Mulder,
J. Solliday, and B. Clarke.
1989.
In vitro susceptibility studies of vancomycin-resistant Enterococcus faecalis.
Antimicrob. Agents Chemother.
33:1588-1591 |
| 23. | Samet, A., M. Bronk, A. Hellmann, and J. Kur. 1999. Isolation and epidemiological study of vancomycin-resistant Enterococcus faecium from patients of a haematological unit in Poland. J. Hosp. Infect. 41:137-143[CrossRef][Medline]. |
| 24. |
Sanger, F.,
S. Nicklen, and A. R. Coulson.
1977.
DNA sequencing with chain-terminating inhibitors.
Proc. Natl. Acad. Sci. USA
74:5463-5467 |
| 25. |
Suppola, J. P.,
E. Kolho,
S. Salmenlinna,
E. Tarkka,
J. Vuopio-Varkila, and M. Vaara.
1999.
vanA and vanB incorporate into an endemic ampicillin-resistant vancomycin-sensitive Enterococcus faecium strain: effect on interpretation of clonality.
J. Clin. Microbiol.
37:3934-3939 |
| 26. | Tenover, F. C., R. Arbeit, V. Goering, P. Mickelsen, B. M. Murray, D. Pershing, and B. Swaminathan. 1995. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J. Clin. Microbiol. 33:2233-2239[Medline]. |
| 27. | Uttley, A. H. C., R. C. George, J. Naidoo, N. Woodford, A. P. Johnson, C. H. Collins, D. Morrison, A. J. Gilfillan, L. E. Fitch, and J. Heptonstall. 1989. High-level vancomycin-resistant enterococci causing hospital infections. Epidemiol. Infect. 103:173-181[Medline]. |
| 28. | Werner, G., I. Klare, and W. Witte. 1997. Arrangement of the vanA gene cluster in enterococci of different ecological origin. FEMS Microb. Lett. 155:55-61[CrossRef][Medline]. |
| 29. |
Woodford, N.,
B. L. Jones,
Z. Baccus,
H. A. Ludlam, and D. F. J. Brown.
1995.
Linkage of vancomycin and high-level gentamicin resistance genes on the same plasmid in a clinical isolate of Enterococcus faecalis.
J. Antimicrob. Chemother.
35:179-184 |
| 30. |
Zar ba, T., and W. Hryniewicz.
1995.
Patterns of antibiotic resistance among enterococcal strains isolated from clinical specimens and food in Poland.
Eur. J. Clin. Microbiol. Infect. Dis.
14:69-71[CrossRef][Medline].
|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Antimicrob. Agents Chemother. | Clin. Microbiol. Rev. |
|---|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|